We have previously shown using a water maze task that transient 2 vessel occlusion (T2VO) induced learning deficit in mice and that the deficit was prevented by pre-treatment of mice with chotosan, a Kampo prescription. In this study, we investigated the mechanism underlying the preventive effect of chotosan on T2VO-induced learning deficit. Chotosan administration 1 h before T2VO operation prevented learning impairment. The extract of Uncaria, a major constituent of chotosan, also had a protective effect on learning impairment in T2VO mice, whereas Uncaria-free chotosan had no beneficial effect on maze performance of T2VO mice. The ameliorative effect of chotosan was blocked by pirenzepine, a muscarinic M 1 antagonist, but not by mecamylamine, a nicotinic receptor antagonist. Acetylcholine (ACh) content in the hippocampus of T2VO mice was significantly lower than that in the hippocampus of sham-operated control mice. Chotosan and Uncaria administration attenuated T2VO-induced reduction of ACh levels in the brain. These results suggest that the preventive effect of chotosan on transient ischemia-induced learning impairment is mainly attributable to the effect of Uncaria and that the ameliorative effect is mediated by stimulation of muscarinic M 1 receptor.
People with high blood pressure are at high risk for developing vascular dementia. Thus, the primary treatment to prevent further worsening of vascular dementia is to control the underlying disease such as hypertension.
Chotosan is a Kampo (traditional medicine of Japan) prescription used for treatment of relatively elderly patients with chronic headache or dizziness associated with hypertension. Recently, Terasawa et al. 1) have reported the effectiveness of chotosan in the treatment of cognitive impairments of patients with stroke or hypertension. In previous in vivo studies, we demonstrated that transient ischemia-induced learning deficit was prevented by administration of chotosan and Uncaria, a major constituent of chotosan. 2, 3) Moreover, in vitro studies 4) have suggested that the preventive effects of chotosan are in part due to its phenolic compounds with free radical scavenging activity and indole alkaloid components with antiexcitotoxic activity, [3] [4] [5] [6] since free radical generation 3) and excessive activation of N-methyl-D-aspartate type glutamate receptors are involved in neuronal cell death caused by ischemia. [7] [8] [9] However, less information is available on the mechanisms by which chotosan exerts a protective effect against cerebral ischemia in vivo.
Several lines of evidence indicate that cholinesterase inhibitors increase cerebral blood flow 10) and exert a protective action against ischemia-induced learning deficit and neuronal cell death. 2, 11, 12) Muscarinic receptors appear to be implicated in inhibition of delayed neuronal death after transient ischemia 13, 14) probably via increasing neurotrophic factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). 15) Moreover, stimulation of nicotinic a7 receptors reportedly shows a similar protective effect on ischemia-induced neuronal injury. 16) Thus, cholinergic tone may play an important role in the protection from ischemic injury. In the present study, we investigated whether chotosan exerts a protective effect on ischemia-induced insults through cholinergic systems.
MATERIALS AND METHODS

Animals
Male ICR mice (Japan SLC Inc., Hamamatsu, Japan) were housed in the laboratory animal room maintained at 25Ϯ1°C with 65Ϯ5% humidity on a 12 h light/dark cycle (lights on: 07:30 to 19:30) for at least one week before the start of the experiments. Animals were given food and water ad libitum. A total of 148 mice were used for the experiments. All experiments were conducted in accordance with the Guiding Principles for the Care and Use of Animals in the Field of Physiological Science of the Physiological Society of Japan and had the approval of the Institutional Animal Use and Care Committee of Toyama Medical and Pharmaceutical University.
Transient Ischemia Operation The animals, aged 8 weeks, were anesthetized with sodium pentobarbital (50 mg/ kg, i.p.), and the bilateral common carotid arteries were carefully separated from the cervical sympathetic and vagal nerves through a ventral cervical incision. The arteries were occluded with aneurysm clips for 20 min and hypotension was produced by blood withdrawal (0.3 ml) from the tail during ischemic operation. The animals that received the same surgical operation without carotid clamping and bleeding served as the sham-operated controls.
Water Maze Task Water maze performance of mice was tested using a 1.1 m diameter circular pool according to our previous report. 17) Two days after the operation, mice were subjected to a visible trial (Visible 1) of water maze in which the platform was made visible 1 cm above the water surface. Training trials were performed daily for 5 days 1 day after the visible trial. Mice received 4 trials per day on training trials. Each trial consisted of placing the mouse in the pool at one of 4 start positions 90°apart around the edge of the pool and allowing the mouse to swim to the hidden transparent platform (7 cm in diameter). If the mouse had not found the platform during a 60-s period, it was placed onto the platform by the experimenter. The mouse was allowed to remain on the platform for 10 s before being removed to an opaque highsided plastic chamber for 60 s. The next trial was then performed. For each trial, the latency to reach the platform (escape latency), distance covered, and mean swim speed were recorded via video capture and image analysis using the SMART ® system (Panlab, S.L., Barcelona, Spain). The data for each day were averaged over the 4 trials before being used for statistical analysis. One day after the acquisition trials for 5 d, a single 60 s probe trial was run in which the platform was removed from the pool. The amount of time spent in each of the four imaginary quadrants of the pool was recorded. After the probe trial, a cue trial was again performed to check the vision of all mice.
Assay of Acetylcholine (ACh) Content of the Brain After completion of behavioral experiments, mice were sacrificed by a focal irradiation of microwaves with a strength of 7 kW for 0.9 s using a microwave applicator (Model TMW-4012A, Toshiba, Tokyo, Japan) as previously described. 11, 17) The brain was removed and dissected into 2 regions: the cerebral cortex and hippocampus. These tissues were quickly frozen in liquid nitrogen, weighed and homogenized in 1 ml of an ice-cold 0.1 N perchloric acid solution containing 2 mM ethylhomocholine (as an internal standard) and 0.1 mM Na 2 EDTA with a Polytron homogenizer (PT-10, Kinematica, Switzerland). The homogenate was centrifuged at 10000ϫg for 20 min at 4°C. Following centrifugation, the supernatant was extracted with diethylether and then centrifuged at 2000ϫg for 2 min. The water phase was filtered through a 0.45 mm filter (Cosmospin filter H, Nacalai Tesque Inc., Kyoto, Japan). The amount of ACh in each sample was determined using HPLC-ECD in conjunction with an enzyme reactor (Eicom, Kyoto, Japan).
Drugs Daily dosage (28 g) of chotosan for a human adult is composed of the following materials: Gypsum fibrosum (5 g), Aurantii Nobilis pericarpium (3 g), Ophiopogonis tuber (3 g), Pinelliae tuber (3 g), Hoelen (3 g), Uncariae Uncis cum Ramulus (3 g), Ginseng radix (2 g), Ledebouriellae radix (2 g), Chrysanthemi flos (2 g), Glycyrrhizae radix (1 g) and Zingiberis rhizoma (1 g). Voucher specimens of each sample used in this study were deposited in the Museum of Materia Medica, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University. To prepare the chotosan extract, Gypsum and all the herbs except Uncaria, were mixed with a 10-fold volume of distilled water and left for 1 h at room temperature. The mixture was decocted for 1 h, with Uncaria added for the last 15 min. An extract prepared without adding Uncaria was used as Uncaria-free chotosan. To prepare the Uncaria extract, Uncariae Uncis cum Ramulus was mixed with 10-fold its volume of distilled water, and decocted for 15 min. After filtration, each extract was freeze-dried. The yields of the extract of chotosan, Uncaria-free chotosan and Uncaria were 28, 22.8 and 12.6% in terms of the dried medicinal herbs, respectively. The Gypsum and herbs were purchased from Tochimoto Tenkaido Co., Ltd. (Osaka, Japan). The chotosan extract was dissolved in distilled water and orally administered to mice 60 min before the T2VO operation. Tacrine (9-amino-1,2,3,4-tetrahydroacridine HCl; Sigma Chemical Co., St. Louis, MO, U.S.A.), a reference drug, was dissolved in physiological saline and injected intraperitoneally 30 min before the ligation.
Statistical Analysis All results were expressed as the meanϮS.E.M. The data obtained in the water maze task were analyzed by one-way or two-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test for multiple comparisons among different groups. The neurochemical data were analyzed by one-way ANOVA followed by the Student-Newman-Keuls test. For all tests, differences with pϽ0.05 were considered significant. Figure 1 shows the effects of chotosan and tacrine on water maze performance of T2VO mice. In the visible trials conducted before (Visible 1) and after training trials (Visible 2) (Fig. 1A) (Fig. 1A) .
RESULTS
Water Maze Performance
In the probe test conducted 1 d after 5 d of training (Fig.  1B) , swimming time of the T2VO control mice in the target quadrant where the platform had been located during training was significantly shorter than that of the sham-operated animals [F(1, 18)ϭ20.041, pϽ0.001] (Fig. 1B) . Pretreatment of T2VO mice with tacrine, a cholinesterase inhibitor, significantly prolonged swimming time in the target quadrant [F (1, 16) On the other hand, pretreatment with Uncaria-free chotosan had no effect on learning performance of T2VO mice in the training test [F treatment (1, 17) (Fig. 2B) , whereas Uncaria extract, when given at the doses which were approximately equivalent to the amount of this herb included in chotosan, dose-dependently reduced the escape latency in the training test [F treatment (2, 27) ϭ7.116, pϽ0.01] and prolonged the swimming time in the target quadrant (pϽ0.05) (Figs. 2C, D) .
We, next, examined if the central cholinergic system is involved in the effect of chotosan, since our previous study demonstrated that this prescription enhanced cholinergic activity in a chronic cerebral hypoperfusion model of mice. 17) When pirenzepine, a muscarinic M 1 antagonist, was injected 30 min after chotosan administration, significantly blocked the preventive effect of chotosan on the escape latency to the hidden platform in the training test [F treatment (1, 17) (Fig. 3A) . Pirenzepine also attenuated the ameliorative effect of Uncaria on water maze performance [F treatment (1, 18) ϭ11.925, pϽ0.01] (Fig. 3C) . Similarly, the effect of tacrine on water maze performance of T2VO mice was inhibited by co-administration of pirenzepine [F treatment (1, 16) ϭ28.700, pϽ0.001] (Fig. 3E) (Figs. 3B, D, F) . In contrast to the effect of pirenzepine, mecamylamine, a neuronal nicotinic receptor antagonist, failed to reverse the effects of tacrine [F treatment (1, 17) (1, 17) ϭ0.151, pϭ0.703] on learning performance in the training test (Fig. 4A) . As shown in Fig. 4B , mecamylamine treatment had no effect on chotosan-nor tacrineinduced prolongation of swimming time in the target quadrant in the probe test.
Changes in ACh Levels in the Hippocampus Effects of T2VO on ACh levels in the hippocampus were examined 1 d after completion of behavioral studies. As shown in Table 1 , there is a significant difference among the groups [F (3, 22) ϭ6.112, pϽ0.01]. Post hoc comparisons showed that T2VO mice had a significantly reduced level of ACh in the hippocampus (pϽ0.01). Pretreatment with chotosan, but not with Uncaria-free chotosan, significantly attenuated the reduction of hippocampal ACh level caused by T2VO. Uncaria extract, as well as chotosan, significantly prevented the T2VO-induced decrease in hippocampal ACh levels ( Table  2) . Treatment with pirenzepine significantly abolished the effects of chotosan, Uncaria and tacrine on the hippocampal ACh level in T2VO mice. In contrast, pretreatment with mecamylamine had no effect on reversal of hippocampal ACh level by chotosan and tacrine in T2VO animals ( Table  3) . 1876 Vol. 28, No. 10 
DISCUSSION
This study has demonstrated that chotosan prevents T2VO-induced spatial learning deficits and reduction of the hippocampal acetylcholine level in mice and that Uncaria, a major component herb of chotosan, plays an important role in the effects of chotosan. Moreover, the present results have suggested that muscarinic M 1 receptors but not nicotinic receptors are involved in the preventive effect of chotosan and Uncaria extract.
Pretreatment with chotosan, as well as with a cholinesterase inhibitor tacrine, dose-dependently attenuated T2VO-induced spatial cognitive deficits in a water maze task. It should be noted that when examined the effects of Uncaria extract and Uncaria-free chotosan at the doses that are approximately relevant to the amount included in chotosan, the Uncaria extract but not Uncaria-free chotosan prevented impairment of water maze learning performance caused by T2VO. These findings are consistent with previous reports from this laboratory 2, 3, 17) and further support the idea that the preventive effect of chotosan is mainly attributable to constituents included in the Uncaria extract. 2, 3, 17) A line of evidence indicates that the cholinergic system in the brain plays an important role in learning and memory 18, 19) and that hypofunction of the central cholinergic system causes learning deficits. 20, 21) Moreover, many studies have demonstrated that ischemia causes a reduction of memory and judgment that is associated with the cholinergic dysfunction in affected brain areas 22) and that ischemic insults decreases in ACh level in the affected regions of the brain. [23] [24] [25] Thus, in animals subjected to transient ischemia, an impairment of spatial cognitive performance in a water maze task is likely attributed to dysfunction of the central cholinergic system due to disturbance of energy metabolism and hypoxia in the ischemic brain. Consistent with previous reports from this 3, 11) and other laboratories, 26, 27) we found that transient ischemia caused a significant reduction of the ACh level in the hippocampus and that pretreatment with a cholinesterase inhibitor tacrine produced a protective effect not only on learning deficits but also on the reduction of the hippocampal ACh level in T2VO mice. These findings raise the possibility that tacrine protects the brain against transient ischemic insults by augmenting ACh level in the brain and thereby stimulating at least muscarinic M 1 receptors since the effects of tacrine were blocked by pirenzepine, a selective muscarinic M 1 receptor antagonist, but not by mecamylamine, a nicotinic receptor antagonist.
It is of interest to note that pretreatment with chotosan and Uncaria extract, as well as with tacrine, exerted the protective action against T2VO-induced decrease in the hippocampal ACh level and that the effects was abolished by pirenzepine but not by mecamylamine. Previous studies demonstrated that the neuroprotective effect of chotosan was in part due to its phenolic compounds with free radical scavenging activity and oxindole alkaloid components, such as rhynchophylline and isorhynchophylline, with an anti-excitotoxic activity. [3] [4] [5] [6] 28, 29) Thus, in addition to these pharmacological properties, it is likely that the protective action of chotosan and Uncaria extract on dysfunction of the central cholinergic systems caused by brain ischemia involves stimulation of muscarinic M 1 receptors.
The neuronal mechanism by which tacrine and chotosan exert preventive effects on transient ischemia-induced learning deficit and hippocampal ACh reduction remains unclear. Lines of evidence indicate that a total volume of cerebral blood flow per se is maintained at a stable level within a narrow ranges by the autoregulation mechanism, whereas regional cerebral blood flow can be increased not only by enhancement of glucose metabolism in regional neurons but also by activity of several neuronal systems, 30) particularly a cholinergic system originating from the basal forebrain. 31, 32) Moreover, it has been demonstrated that the cholinergic systems produce vasodilative action in the cerebral cortex and hippocampus, the brain areas quite vulnerable to ischemia. 31) Considering M 1 muscarinic receptor antagonist-reversible properties of the pharmacological action of these drugs observed in present and previous studies, 17) one may infer that tacrine and chotosan improve regional cerebral blood flow during ischemia by enhancing a central cholinergic system, leading to a reduction of ischemic brain damage. However, this possibility may be little since cholinergic vasodilation in the cortex and hippocampus involves muscarinic and nicotinic receptor stimulation. Nevertheless, the mechanism underlying the protective actions of chotosan, Uncaria extract, and tacrine on T2VO-induced neuronal damage needs further investigation.
In previous in vitro studies, rhynchophylline and isorhynchophylline, oxindole alkaloid components of Uncaria species, exhibited antagonistic properties for NMDA type glutamate receptors, muscarinic receptors and 5-HT2 receptors in a receptor expression model of Xenopus oocytes. 5, 6) Moreover, these alkaloids, as well as pirenzepine, the NMDA antagonist (Ϯ)-2-amino-5-phosphono-valeric acid, and the 5-HT2 antagonist ketanserin, protected in vitro ischemia-induced neuronal damage in the hippocampus, 5) suggesting that these alkaloids exerted their protective action against in vitro ischemia-induced neuronal damage via blockade of NMDA, M 1 and 5-HT2 receptors. Therefore, the apparent agonistic properties of chotosan and the Uncaria extract on central cholinergic systems found in this study are in contrast to the action of Uncaria alkaloids observed in the aforementioned in vitro studies. The exact reason for this discrepancy remains unclear. However, considering the previous report that rhynchophylline administered orally before ischemic operation attenuated transient ischemia-induced spatial cognitive performance in mice,
2) the metabolite(s) of the Uncaria alkaloid constituent(s) may play a role in apparent enhancement of central cholinergic systems in the brain. In conclusion, chotosan exerts a protective effect on transient ischemia-induced spatial cognitive impairment and neuronal dysfunction in mice. The effects of chotosan involves stimulation of muscarinic M 1 receptors in the brain. Considering our previous findings that chotosan has an anti-hypertension effect and improved learning performance impaired by permanent occlusion of common carotid arteries in mice, the present findings suggest that this prescription is beneficial for preventing against and curing cerebrovascular dementia.
